JP2022121594A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022121594A5 JP2022121594A5 JP2022104523A JP2022104523A JP2022121594A5 JP 2022121594 A5 JP2022121594 A5 JP 2022121594A5 JP 2022104523 A JP2022104523 A JP 2022104523A JP 2022104523 A JP2022104523 A JP 2022104523A JP 2022121594 A5 JP2022121594 A5 JP 2022121594A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- compound
- administered
- acceptable salt
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 24
- 229960003852 atezolizumab Drugs 0.000 claims 20
- 229940125904 compound 1 Drugs 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 7
- 125000001475 halogen functional group Chemical group 0.000 claims 6
- 208000037843 metastatic solid tumor Diseases 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- BJEPYKJPYRNKOW-UWTATZPHSA-N (R)-malic acid Chemical compound OC(=O)[C@H](O)CC(O)=O BJEPYKJPYRNKOW-UWTATZPHSA-N 0.000 claims 2
- 230000000405 serological effect Effects 0.000 claims 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023222710A JP2024019720A (ja) | 2017-01-20 | 2023-12-28 | がんを治療するためのカボザンチニブとアテゾリズマブの組み合わせ |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762448869P | 2017-01-20 | 2017-01-20 | |
| US62/448,869 | 2017-01-20 | ||
| US201762458447P | 2017-02-13 | 2017-02-13 | |
| US62/458,447 | 2017-02-13 | ||
| PCT/US2018/014523 WO2018136796A1 (en) | 2017-01-20 | 2018-01-19 | Combinations of cabozantinib and atezolizumab to treat cancer |
| JP2019539223A JP7222895B2 (ja) | 2017-01-20 | 2018-01-19 | がんを治療するためのカボザンチニブとアテゾリズマブの組み合わせ |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019539223A Division JP7222895B2 (ja) | 2017-01-20 | 2018-01-19 | がんを治療するためのカボザンチニブとアテゾリズマブの組み合わせ |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023222710A Division JP2024019720A (ja) | 2017-01-20 | 2023-12-28 | がんを治療するためのカボザンチニブとアテゾリズマブの組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022121594A JP2022121594A (ja) | 2022-08-19 |
| JP2022121594A5 true JP2022121594A5 (https=) | 2022-11-17 |
Family
ID=61569414
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019539223A Active JP7222895B2 (ja) | 2017-01-20 | 2018-01-19 | がんを治療するためのカボザンチニブとアテゾリズマブの組み合わせ |
| JP2022104523A Pending JP2022121594A (ja) | 2017-01-20 | 2022-06-29 | がんを治療するためのカボザンチニブとアテゾリズマブの組み合わせ |
| JP2023222710A Pending JP2024019720A (ja) | 2017-01-20 | 2023-12-28 | がんを治療するためのカボザンチニブとアテゾリズマブの組み合わせ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019539223A Active JP7222895B2 (ja) | 2017-01-20 | 2018-01-19 | がんを治療するためのカボザンチニブとアテゾリズマブの組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023222710A Pending JP2024019720A (ja) | 2017-01-20 | 2023-12-28 | がんを治療するためのカボザンチニブとアテゾリズマブの組み合わせ |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11198731B2 (https=) |
| EP (1) | EP3570840B1 (https=) |
| JP (3) | JP7222895B2 (https=) |
| KR (2) | KR102610764B1 (https=) |
| CN (4) | CN117205312A (https=) |
| AU (2) | AU2018210397B2 (https=) |
| BR (1) | BR112019015011A2 (https=) |
| CA (1) | CA3049452A1 (https=) |
| ES (1) | ES3031468T3 (https=) |
| IL (1) | IL268138B (https=) |
| MA (1) | MA47310A (https=) |
| MX (2) | MX389966B (https=) |
| UA (1) | UA126970C2 (https=) |
| WO (1) | WO2018136796A1 (https=) |
| ZA (1) | ZA201904652B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME03376B (me) | 2010-05-20 | 2020-01-20 | Array Biopharma Inc | Makrociklička jedinjenja kао inhibiтori trk kinaze |
| EP3174854B1 (en) | 2014-07-31 | 2022-08-24 | Exelixis, Inc. | Method of preparing fluorine-18 labeled cabozantinib and its analogs |
| EP3442531A1 (en) | 2016-04-15 | 2019-02-20 | Exelixis, Inc. | Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
| WO2018136661A1 (en) | 2017-01-18 | 2018-07-26 | Andrews Steven W | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS |
| US11198731B2 (en) * | 2017-01-20 | 2021-12-14 | Exelixis, Inc. | Combinations of cabozantinib and atezolizumab to treat cancer |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TWI876442B (zh) | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| EP3740490A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| JP7060694B2 (ja) | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物 |
| US11472802B2 (en) | 2018-01-18 | 2022-10-18 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors |
| CN117402114A (zh) | 2018-01-26 | 2024-01-16 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| TWI831259B (zh) | 2018-06-15 | 2024-02-01 | 漢達生技醫藥股份有限公司 | 包含達沙替尼十二烷基硫酸鹽組合物的膠囊 |
| JP7653352B2 (ja) * | 2018-09-05 | 2025-03-28 | エクスプレステック、リミテッド、ライアビリティ、カンパニー | 免疫グロブリンａ製剤 |
| CN112996794A (zh) | 2018-09-10 | 2021-06-18 | 阿雷生物药品公司 | 作为ret激酶抑制剂的稠合杂环化合物 |
| US12138351B2 (en) * | 2020-04-14 | 2024-11-12 | Janssen Biotech, Inc. | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof |
| IL300151A (en) * | 2020-07-31 | 2023-03-01 | Exelixis Inc | Combinations for cancer treatment |
| WO2022040555A2 (en) * | 2020-08-21 | 2022-02-24 | Exelixis, Inc. | Method of treating cancer |
| WO2022197900A1 (en) * | 2021-03-19 | 2022-09-22 | Merck Sharp & Dohme Llc | Methods for treating cancer with anti-ilt3 antibodies |
| US11620580B2 (en) * | 2021-04-01 | 2023-04-04 | Banjo Health Inc. | Methods and systems for probabilistic filtering of candidate intervention representations |
| WO2024163400A1 (en) | 2023-01-31 | 2024-08-08 | Handa Oncology, Llc | Improved cabozantinib compositions and methods of use |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2210607B1 (en) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| US20080200515A1 (en) | 2006-12-29 | 2008-08-21 | Tap Pharmaceutical Products Inc. | Solid state forms of enantiopure ilaprazole |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| NZ779754A (en) | 2009-01-16 | 2023-04-28 | Exelixis Inc | Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
| EA030435B1 (ru) | 2010-07-16 | 2018-08-31 | Экселиксис, Инк. | ТАБЛЕТКА, СОДЕРЖАЩАЯ МОДУЛЯТОР c-MET В ФОРМЕ КРИСТАЛЛИЧЕСКОЙ L-МАЛАТНОЙ СОЛИ (ВАРИАНТЫ), СПОСОБ ЕЕ ПРОИЗВОДСТВА И СПОСОБ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКОГО ЗАБОЛЕВАНИЯ С ЕЕ ИСПОЛЬЗОВАНИЕМ |
| WO2014165779A1 (en) * | 2013-04-04 | 2014-10-09 | Exelixis, Inc. | Drug combinations to treat cancer |
| BR112016018450A2 (pt) * | 2014-02-14 | 2018-09-18 | Exelixis Inc | formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso |
| EP3442531A1 (en) | 2016-04-15 | 2019-02-20 | Exelixis, Inc. | Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
| CN109475545A (zh) * | 2016-04-19 | 2019-03-15 | 埃克塞里艾克西斯公司 | 三阴性乳腺癌治疗方法 |
| US11198731B2 (en) | 2017-01-20 | 2021-12-14 | Exelixis, Inc. | Combinations of cabozantinib and atezolizumab to treat cancer |
-
2018
- 2018-01-19 US US16/479,143 patent/US11198731B2/en active Active
- 2018-01-19 UA UAA201909420A patent/UA126970C2/uk unknown
- 2018-01-19 CN CN202311144073.3A patent/CN117205312A/zh active Pending
- 2018-01-19 CN CN201880013200.7A patent/CN110352057A/zh active Pending
- 2018-01-19 IL IL268138A patent/IL268138B/en unknown
- 2018-01-19 ES ES18709192T patent/ES3031468T3/es active Active
- 2018-01-19 KR KR1020197024015A patent/KR102610764B1/ko active Active
- 2018-01-19 JP JP2019539223A patent/JP7222895B2/ja active Active
- 2018-01-19 CN CN202311144084.1A patent/CN117771363A/zh active Pending
- 2018-01-19 CN CN202311144074.8A patent/CN117205313A/zh active Pending
- 2018-01-19 MA MA047310A patent/MA47310A/fr unknown
- 2018-01-19 MX MX2019008032A patent/MX389966B/es unknown
- 2018-01-19 CA CA3049452A patent/CA3049452A1/en active Pending
- 2018-01-19 AU AU2018210397A patent/AU2018210397B2/en active Active
- 2018-01-19 WO PCT/US2018/014523 patent/WO2018136796A1/en not_active Ceased
- 2018-01-19 BR BR112019015011A patent/BR112019015011A2/pt not_active Application Discontinuation
- 2018-01-19 EP EP18709192.1A patent/EP3570840B1/en active Active
- 2018-01-19 KR KR1020237041680A patent/KR20230169458A/ko not_active Ceased
-
2019
- 2019-07-03 MX MX2022001718A patent/MX2022001718A/es unknown
- 2019-07-16 ZA ZA2019/04652A patent/ZA201904652B/en unknown
-
2021
- 2021-11-04 US US17/519,327 patent/US20220056138A1/en not_active Abandoned
-
2022
- 2022-06-29 JP JP2022104523A patent/JP2022121594A/ja active Pending
-
2023
- 2023-12-28 JP JP2023222710A patent/JP2024019720A/ja active Pending
-
2024
- 2024-05-24 AU AU2024203472A patent/AU2024203472A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022121594A5 (https=) | ||
| JP2021098728A5 (https=) | ||
| JP2020514311A5 (https=) | ||
| CN115624550B (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
| JP2006523216A5 (https=) | ||
| JP2017031160A5 (https=) | ||
| JP2022519744A5 (https=) | ||
| JP2006507308A5 (https=) | ||
| EP2968226B1 (en) | Oxprenolol compositions for treating cancer | |
| JP2024533423A5 (https=) | ||
| JP2023548055A5 (https=) | ||
| JP2023553533A5 (https=) | ||
| JP2021530554A5 (https=) | ||
| JP2012522841A5 (https=) | ||
| JP6656397B2 (ja) | 抗腫瘍薬物の効果を有する併用薬物 | |
| JP2025500826A5 (https=) | ||
| JP2023503167A5 (https=) | ||
| JP2024502446A5 (https=) | ||
| JP2024516359A5 (https=) | ||
| JP2021511344A5 (https=) | ||
| JP2019519563A5 (https=) | ||
| JP2025509278A5 (https=) | ||
| JP2022544559A5 (https=) | ||
| CA2552855A1 (en) | Azabicyclooctan-3-one derivatives and use thereof | |
| CN117959315B (zh) | 化合物pgg作为krasg12d抑制剂mrt1133的增效剂联合治疗胰腺癌的应用 |